Browsing Clinical Studies by subject "Radiation Dose Hypofractionation"

Now showing items 1-10 of 10

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Dearnaley, D; Syndikus, I; Mossop, H; Khoo, V; Birtle, A; Bloomfield, D; Graham, J; Kirkbride, P; Logue, J; Malik, Z; Money-Kyrle, J; O'Sullivan, JM; Panades, M; Parker, C; Patterson, H; Scrase, C; Staffurth, J; Stockdale, A; Tremlett, J; Bidmead, M; Mayles, H; Naismith, O; South, C; Gao, A; Cruickshank, C; Hassan, S; Pugh, J; Griffin, C; Hall, E; CHHiP Investigators (2016-08)

<h4>Background</h4>Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects ...
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Wilson, JM; Dearnaley, DP; Syndikus, I; Khoo, V; Birtle, A; Bloomfield, D; Choudhury, A; Graham, J; Ferguson, C; Malik, Z; Money-Kyrle, J; O'Sullivan, JM; Panades, M; Parker, C; Rimmer, Y; Scrase, C; Staffurth, J; Stockdale, A; Cruickshank, C; Griffin, C; Hall, E; CHHiP Investigators (2018-04)

<h4>Purpose</h4>Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial ...
Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.

Naismith, OF; Griffin, C; Syndikus, I; South, C; Mayles, H; Mayles, P; Khoo, V; Scrase, C; Graham, J; Hassan, S; Hall, E; Dearnaley, DP; CHHiP Investigators (2019-09)

<h4>Aims</h4>The CHHiP (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy In Prostate Cancer; CRUK/06/016) trial investigated hypofractionated radiotherapy for localised prostate cancer. Forward- ...
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; Bloomfield, DJ; Chan, C; Churn, M; Cleator, S; Coles, CE; Goodman, A; Harnett, A; Hopwood, P; Kirby, AM; Kirwan, CC; Morris, C; Nabi, Z; Sawyer, E; Somaiah, N; Stones, L; Syndikus, I; Bliss, JM; Yarnold, JR; FAST-Forward Trial Management Group (2020-05)

<h4>Background</h4>We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international ...
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins, A; Mossop, H; Syndikus, I; Khoo, V; Bloomfield, D; Parker, C; Logue, J; Scrase, C; Patterson, H; Birtle, A; Staffurth, J; Malik, Z; Panades, M; Eswar, C; Graham, J; Russell, M; Kirkbride, P; O'Sullivan, JM; Gao, A; Cruickshank, C; Griffin, C; Dearnaley, D; Hall, E (2015-12)

<h4>Background</h4>Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after ...
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Brand, DH; Tree, AC; Ostler, P; van der Voet, H; Loblaw, A; Chu, W; Ford, D; Tolan, S; Jain, S; Martin, A; Staffurth, J; Camilleri, P; Kancherla, K; Frew, J; Chan, A; Dayes, IS; Henderson, D; Brown, S; Cruickshank, C; Burnett, S; Duffton, A; Griffin, C; Hinder, V; Morrison, K; Naismith, O; Hall, E; van As, N; PACE Trial Investigators (2019-11)

<h4>Background</h4>Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic ...
Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.

Haviland, JS; Mannino, M; Griffin, C; Porta, N; Sydenham, M; Bliss, JM; Yarnold, JR; START Trialists' Group (2018-01)

<h4>Background and purpose</h4>Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with ...
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.

Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; Yarnold, JR; Bliss, JM; Coles, CE; IMPORT Trialists (2019-02)

<h4>Purpose</h4>IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ...
Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

Naismith, O; Mayles, H; Bidmead, M; Clark, CH; Gulliford, S; Hassan, S; Khoo, V; Roberts, K; South, C; Hall, E; Dearnaley, D; CHHiP Investigators (2019-09)

<h4>Aims</h4>The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was ...
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.

Murray, J; Griffin, C; Gulliford, S; Syndikus, I; Staffurth, J; Panades, M; Scrase, C; Parker, C; Khoo, V; Dean, J; Mayles, H; Mayles, P; Thomas, S; Naismith, O; Baker, A; Mossop, H; Cruickshank, C; Hall, E; Dearnaley, D; CHHiP Investigators (2020-01)

<h4>Background and purpose</h4>Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced ...

Publications Repository

Publications Repository

Browsing Clinical Studies by subject "Radiation Dose Hypofractionation"

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.

Browsing Clinical Studies by subject "Radiation Dose Hypofractionation"

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. ﻿

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. ﻿

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity. ﻿

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. ﻿

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. ﻿

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. ﻿

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. ﻿

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. ﻿

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer. ﻿

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. ﻿

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.